Clinical Trial Update: Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiolabeled SMT-487 (Yttrium-90-DOTA-Tyr3-octreotide) in patients with refractory small cell lung cancer or metastatic breast cancer h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Radiolabeled SMT-487 (Yttrium-90-DOTA-Tyr3-octreotide) (yttrium-90 DOTA-Tyr3-octreotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer, Lung Cancer | Phase 2 | Status: COMPLETED